-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ASipsmViTM0zIgk0h9o3xQf8yb2k0Fo87+l2NMa11fIMGR6lcbGEZ5QnsZxcirAy WReo2pNcTlcxM/CLed8KAQ== 0000950109-96-004326.txt : 19960710 0000950109-96-004326.hdr.sgml : 19960710 ACCESSION NUMBER: 0000950109-96-004326 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 19960628 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 19960709 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE CENTRAL INDEX KEY: 0000094784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870277826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-06533 FILM NUMBER: 96592275 BUSINESS ADDRESS: STREET 1: 1601 TRAPELO RD STREET 2: RESERVOIR PL CITY: WALTHAM STATE: MA ZIP: 02154 BUSINESS PHONE: 6178908263 MAIL ADDRESS: STREET 2: 1601 TRAPELO RD CITY: WALTHAN STATE: MA ZIP: 02154 FORMER COMPANY: FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE DATE OF NAME CHANGE: 19790521 8-K 1 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) June 28, 1996 -------------------- BOSTON LIFE SCIENCES, INC. -------------------------- (Exact name of registrant as specified in its charter) Delaware 0-6533 87-0277826 -------- ------ -------------------------------- (State or other jurisdiction of (Commission (I.R.S. Employer Identification No.) incorporation or organization) File No.) 33 Newbury Street, Suite 300 Boston, Massachusetts 02116 - --------------------------------------- ----------- (Address of principal executive offices) Zip Code Registrant's telephone number, including area code (617) 425-0200 ----------------- Item 5. Other Events. ------------ The Company completed, on June 28, 1996, a private placement of 5,000,000 shares of Common Stock, par value $.01 per share, raising approximately $5 million in gross proceeds. The net proceeds of the sale are expected to be used for research and development of certain of the Company's newest proposed products and programs, including, for example, a recently discovered transcription factor called C-Maf, as to which the Company has previously filed a report on Form 8-K. The Company issued two press releases regarding this closing on July 3, 1996 and July 8, 1996 and both press releases in their entirety are filed as exhibits to this report and are incorporated herein by such reference. Item 7. Exhibits. -------- The following Exhibits are filed as part of this Report on Form 8-K: (c) Exhibits 99.1 Press Release, dated July 3, 1996. 99.2 Press Release, dated July 8, 1996. -2- SIGNATURES ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BOSTON LIFE SCIENCES, INC. Dated: July 9, 1996 By: /s/ S. David Hillson ------------------------------------- President and Chief Executive Officer -3- BOSTON LIFE SCIENCES, INC. CURRENT REPORT ON FORM 8-K EXHIBIT INDEX Exhibit No. Page - ----------- ---- 99.1 Press Release, dated July 3, 1996 5 99.2 Press Release, dated July 8, 1996 6 EX-99.1 2 PRESS RELEASE Exhibit 99.1 ***FOR IMMEDIATE RELEASE*** BOSTON LIFE SCIENCES RAISES $5 MILLION IN ADDITIONAL CAPITAL Boston, MA - July 3, 1996 - Boston Life Sciences, Inc. (Nasdaq: BLSI) announced that it has completed a private placement of 5,000,000 shares of Common Stock, raising approximately $5 million in gross proceeds. Such shares have not been registered under the Securities Act of 1933 and may not be sold in the United States absent registration under the Act or an exemption from such registration requirements. "We are very pleased that the private placement was fully subscribed," stated David Hillson, president and chief executive officer of BLSI. BLSI merged in June 1995 with and into Greenwich Pharmaceuticals Incorporated, which was then renamed "Boston Life Sciences, Inc." BLSI is developing novel treatments for cancel, autoimmune diseases, and central nervous system disorders. BLSI's products include, among others, THEREAFECTIN(R) (amiprilose HCI), a potential treatment for rheumatoid arthritis; Cartilage derived Inhibitor (CDI), a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane/TM/, a radioimaging agent for the diagnosis of Parkinson's Disease; and a transcription factor that controls the expression of molecules associated with autoimmune disease. For additional information contact: S. David Hillson President and CEO 212-832-4373 ### EX-99.2 3 PRESS RELEASE (JULY 8, 1996) Exhibit 99.2 ***FOR IMMEDIATE RELEASE*** BOSTON LIFE SCIENCES TO USE NEW EQUITY PROCEEDS FOR RESEARCH AND DEVELOPMENT OF T-CELL SWITCH APPLICATIONS Boston, MA - July 8, 1996 - Boston Life Sciences, Inc. (Nasdaq: BLSI) announced that it expects to use much of the approximately $5 million raised in its recently completed private placement of common stock to support and pursue research and development of a newly-discovered T-cell switch factor called C-MAF, which the Company recently licensed from Harvard University. The majority of the equity was placed with institutional investors. "The proceeds from this most recent placement increases the net capital raised this year to over $27 million, which will permit us to provide significant sources for this exciting T-cell switch technology without requiring us to limit our commitment or divert funds away from our other development projects", said David Hillson, president and chief executive officer of BLSI. "Although C-MAF is at an early state of development and will require significant time and money before any product is realized, we are gratified at the reaction to our private placement and to have received funds to apply to a new and exciting opportunity." BLSI is engaged in the research and development of novel treatments for cancer, autoimmune diseases, and central nervous system disorders. BLSI's products in clinical trials or in pre-clinical development include Cartilage-derived Inhibitor (CDI), a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane/(TM)/a radioimaging agent for the diagnosis of Parkinson's Disease; THEREAFECTIN/(R)/ for the treatment of Rheumatoid Arthritis; and a different transcription factor that controls the expression of molecules associated with autoimmune disease. For additional information contact: S. David Hillson President and CEO 212-832-4373 ### -----END PRIVACY-ENHANCED MESSAGE-----